Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.

ABSTRACT: Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective medications for the treatment of type 2 diabetes and obesity. Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition. Yet, the association between GLP-1 RAs and non-MTC remains controversial. Excessive worry about unproven thyroid cancer risk might lead to underutilizing GLP-1 RAs in patients who could otherwise experience substantial benefits. Unwarranted concerns about thyroid cancer could lead to unnecessary thyroid cancer screening and harms from overdiagnosis. Summary: The body of evidence assessing

SUBMITTER: Espinosa De Ycaza AE 

PROVIDER: S-EPMC10998705 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature